Company Details. The FDA is expected to decide on AXS-07's NDA by Apr 30, 2022. Major Depressive Disorder - Pipeline Insight, 2021. AXSM 13F Hedge Fund and Asset Management Owners 5,900 shares were traded during mid-day trading, a decline of 99% from the average session volume of 697,404 shares. The story hasn't been so great, though, for Axsome Therapeutics (NASDAQ:AXSM). Axsome secures debt funding of $225M from Hercules Capital ... Axsome Therapeutics Inc. company facts, information and financial ratios from MarketWatch. Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2021. Axsome Therapeutics (AXSM): >>> Could Biogen Acquire ... Axsome Therapeutics (NASDAQ: AXSM) was said to be added to the takeout watch list at $180-$200 at William Blair following today's Pfizer deal. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Axsome's core CNS product candidate portfolio includes four clinical-stage candidates, which we are developing for six different CNS . Axsome Therapeutics. and has now fallen 4 days in a row.During the day the stock fluctuated 7.56% from a day low at $31.76 to a day high of $34.16.The price has been going up and down for this period, and there has been a -5.21% loss for the last 2 weeks. Naren Kossuri Executive Director, Head Of Commercial Operations at Axsome Therapeutics, Inc. The analyst cites the company's AXS-05 lead asset having been "de-risked" by . In depth view into Axsome Therapeutics Debt-to-Equity explanation, calculation, historical data and more Investors who have lost money in their . Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer. Axsome Therapeutics, Inc. AXSM announced that the FDA has accepted its new drug application (NDA) for its novel, oral, multi-mechanistic investigational candidate, AXS-07. Axsome Therapeutics. Axsome is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and . That's certainly the case for Axsome. Axsome Therapeutics announced that it had entered into an agreement with Pfizer for two products.One was the clinical and non-clinical data for reboxetine, which is the active ingredient in AXS . The Smoking Cessation Pipeline report embraces in-depth commercial and clinical assessment of the Smoking Cessation pipeline products from the pre-clinical developmental phase to the marketed phase.. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. Axsome Therapeutics initiated with a Buy at SunTrust. 2.Vesting. Buyout fever has sparked a renewed interest in small to mid-cap biotech stocks of late. Agreement . The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS . Buyout fever has sparked a renewed interest in small to mid-cap biotech stocks of late. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which . In depth view into Axsome Therapeutics 3-Year Average Share Buyback Ratio explanation, calculation, historical data and more Axsome Therapeutics, Inc. Stock Unit Agreement under the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan. The FDA has concerns with Axsome's lead and potential blockbuster drug to treat major depressive disorder, which sent the company's stock price down by more than 40% early Monday. see r/AUPH subreddit. See r/AUPH subreddit. The story hasn't been so great, though, for Axsome Therapeutics (NASDAQ: AXSM). Shares of Axsome Therapeutics soared more than 3500% last year after the company has announced a number of positive clinical trial results in 2019. Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer . A look at the stock's price movement, the close in the last trading session was $31.74, moving within a range at $ Berenberg analyst Esther Hong initiates coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Buy rating and a price target of $112.00. Its pipeline products include AXS-05, AXS-07, AXS-12, and others. 3. AXSM Debt-to-Equity as of today (December 14, 2021) is 1.17. However, such a meltdown does make a company much cheaper for a potential acquisition. SELECT AN OPTION . Post-Market 0.00 (0.00%) 2. AXS-12 is a novel, oral, potent, and highly . Unless otherwise provided in this Agreement, capitalized terms used herein are defined in the Glossary at the end of this Agreement. Merger & Acquisition 11.4.2. The IPO was closed on November 24. Axsome Therapeutics Inc. (NASDAQ:AXSM) price on Friday, October 08, rose 1.45% above its previous day's close as an upside momentum from buyers pushed the stock's value to $32.20. Its platform helps customers to access medical care for . The NDA is seeking approval of AXS-07 as a potential acute treatment of migraine. Axsome Therapeutics Inc insider trades are shown in the following chart. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing . Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Axsome Therapeutics (NASDAQ:AXSM) has announced a $225M term loan facility with Hercules Capital, which is expected to strengthen its financial position through the anticipated commercial launches . Denali Therapeutics (DNLI): Announced that its partner Sanofi has commenced dosing in a Phase 2 study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with cutaneous lupus erythematosus (CLE). Pizzie Nick sec form 4 filings insider trading, stock buying and selling. Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) traded up 6.6% during trading on Friday following insider buying activity. Get the latest NRX Pharmaceuticals Inc (NRXP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. According to the issued ratings of 12 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Buy based on the current 1 hold rating and 11 buy ratings for AXSM. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Attractive price. 5. That's certainly the case for Axsome. The company's stock price has collected -1.03% of loss in the last five trading sessions. The analyst commented, "Our Buy recommendation for Axsome . Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others . Please select an option from the list below. Axsome Therapeutics, Inc. is a biopharmaceutical company. AXSM Axsome Therapeutics $24.73 / +1.16 (+4.92%) 05/28/19 Truist Axsome Therapeutics initiated with a Buy at SunTrust 05/23/19 H.C. Wainwright Axsome Therapeutics price target raised to $30 from $23 at H.C. Wainwright 04/15/19 H.C. Wainwright Axsome Therapeutics price target raised to $23 from $18 at H.C. Wainwright 04/08/19 SVB Leerink Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. . Hims & Hers Health, Inc., formerly Oaktree Acquisition Corp., is a telehealth platform that connects consumers to licensed healthcare professionals. This "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline . Attractive price. The report covers collaborations, acquisition, merger, licensing, and patent details for Musculoskeletal Pain emerging therapies. The average twelve-month price target for Axsome Therapeutics is $100.28 with a high price target of $180.00 and a low price target of $34.00. Buyout or not, Aurinia's shares are arguably a steal at these levels. The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. Find the latest Axsome Therapeutics, Inc., AXSM stock market data. I think it was Jeffs who convinced KL to join AXSM in Jan 2021 after DOVA's buyout in late 2019. Message board - Online Community of active, educated investors researching and discussing Axsome Therapeutics, Inc. Stocks. Axsome Therapeutics, Inc. - Hold. See r/AXSM subreddit. A community of investors in the legal psychedelics industry. $100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to . AXSM 3-Year Average Share Buyback Ratio as of today (November 30, 2021) is -13.60. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. "Despite this mind-boggling rally, there is still significant upside potential in the stock for 2020," according to Seeking Alpha analysis. AXSM: Axsome Therapeutics, Inc. - Insider Transactions Get the latest Insider Transactions for Axsome Therapeutics, Inc. from Zacks Investment Research Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 . Veeva is the leader in cloud solutions for . AXSM 30.70 1.85 (5.68%). 48.9k members in the shroomstocks community. There aren't many positives when a biotech stock crashes more than 70%. Axsome Therapeutics. . Moving outside the oncology space, Axsome Therapeutics . Learn more. Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, and Veeva Systems (NYSE: VEEV), today announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC™) platform. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. DUBLIN, October 05, 2021--(BUSINESS WIRE)--The "Smoking Cessation and Nicotine Addiction - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.. Axsome Therapeutics, Inc. "As part of the ongoing review of our NDA for AXS-05, the . Axsome Therapeutics. Investors who have lost money in their Axsome Therapeutics investment should contact the firm to learn more about how they might recover those losses. The firm would make a logical bite-size acquisition for anyone that wanted to expand their footprint in oncology. Axsome Therapeutics, Inc. AXSM announced that it is accelerating the completion time of the phase II/III ADVANCE-1 study, which currently evaluates AXS-05 for the treatment of agitation associated . On December 16, the stock rose again by more than 70% after the presentation of the results for its late-stage depression drug AXS-05. Oncology Therapeutics Turning the Tide on Cancer Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. Axsome Therapeutics' well differentiated CNS pipeline may make it a top takeover target. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. Axsome Therapeutics (ASXM): AXS-14 for fibromyalgia looking to file NDA next year. The Axsome Therapeutics stock price fell by -1.81% on the last day (Monday, 13th Dec 2021) from $33.15 to $32.55. Axsome Therapeutics is a clinical-stage biotech company developing innovative drugs for the treatment of central nervous system (CNS) disorders such as depression and migraine. This product is a clinical trials report. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome Therapeutics, Inc. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) resulting from allegations that Axsome may have issued materially misleading business information to the investing public. The average twelve-month price target for Axsome Therapeutics is $100.28 with a high price target of $180.00 and a low price target of $34.00. Contacts. Axsome Therapeutics EPS beats by $0.03 Seeking Alpha - 11/8/2021 7:03:53 AM: Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/8/2021 7:00:00 AM: Axsome Therapeutics Q3 2021 Earnings Preview Seeking Alpha - 11/5/2021 2:15:06 PM Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. However, such a meltdown does make a company much cheaper for a potential acquisition. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office . 1.Terminology. Insiders are officers, directors, or significant investors in a company. see r/AXSM subreddit. The company traded as high as $38.79 and last traded at $37.95. Axsome Therapeutics, Inc. (NASDAQ:AXSM) said it has enrolled the first patient in SYMPHONY, a Phase 3 study of AXS-12 in patients with narcolepsy. Axsome Therapeutics stock increased by almost 3,600 percent during 2019. Axsome Contact: Mark Jacobson Vice President, Operations Axsome Therapeutics, Inc. 25 Broadway, 9th Floor New York, NY 10004 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com Contact close JEFFs was the CEO at United Therapeutics for 18 yrs so he knows KL's work well because KL . Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer. According to the issued ratings of 12 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Buy based on the current 1 hold rating and 11 buy ratings for AXSM. Price From: €1833 EUR $2,000 USD £1,553 GBP. Get a full understanding of how Axsome Therapeutics, Inc. is performing with stock quotes and prices, as well as real-time news . For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information. However, such a meltdown does make a company much cheaper for a potential acquisition. BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) for potential securities law violations. Learn more. NEW YORK, December 4, 2015: Morgan Lewis represented biopharmaceutical company Axsome Therapeutics (NASDAQ:AXSM) in the closing of its initial public offering of nearly 5.7 million shares of common stock at a public offering price of $9.00 per share. Axsome Therapeutics' well differentiated CNS pipeline may make it a top takeover target . "Axsome Therapeutics is set to grab a large share in the major depressive disorder indication." View Pricing. Monday morning he uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million — $300 million in cash and $80 million for a premium equity deal — to jump on board the biotech . Shares of Axsome Therapeutics rose more than 3500% in 2019 after the company has achieved significant progress with its clinical research pipeline. Company to host conference call today at 8:00 AM Eastern NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies . There aren't many positives when a biotech stock crashes more than 70%. Axsome Therapeutics NASDAQ Updated Dec 14, 2021 10:36 PM. Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others Read full article December 15, 2021, 10:00 AM . on . Attractive price. Contact Data CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For . on . Axsome Therapeutics, Inc. Report this profile About As Technology team lead and perpetual learner I apply my deep toolkit and international experience in firms of all sizes across China, Europe . The Company has designed and build a cloud-based technology, through which i t offers a range of health and wellness products and services. 212-203-5072. www.axsome.com. Press Release reported 4 hours ago that Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major . While the . Each license type allows a set number of users to access the report. The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS . BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) — Block & Leviton is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) for potential securities law violations. Axsome Therapeutics (NASDAQ: AXSM) stock is now trading at a 60% discount compared to its 52-week high. Greater Seattle Area 402 connections 25 BROADWAY, 9TH FLOOR, NEW YORK, NY 10004. Axsome Therapeutics' well-differentiated CNS pipeline may make it a top takeover target. Zacks' proprietary data indicates that Axsome Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the AXSM shares . There aren't many positives when a biotech stock crashes more than 70%. Axsome Therapeutics Inc. (NASDAQ:AXSM) went up by 14.71% from its latest closing price compared to the recent 1-year high of $109.53. Axsome Therapeutics Biosplice Therapeutics Braeburn . Global drug policy is changing, and … DUBLIN, Dec. 15, 2021 /PRNewswire/ -- The "Smoking Cessation & Nicotine De-Addiction Product Market Research Report by Product, Distribution, and Region. The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the . All of the RSUs are nonvested and forfeitable as of the Grant . SunTrust analyst Joon Lee initiated Axsome Therapeutics with a Buy rating and a price target of $50, saying that although the stock has multiplied about 10-times year-to-date, it remains "significantly undervalued".

Art By Insane Asylum Inmates, Ashford Tile Reviews, Rudbeckia Maxima Seeds Canada, The Limehouse Golem What Did Lizzie's Mother Do To Her, Otf Knife Not Retracting, Hotel Discounts For Healthcare Workers Hilton, Oreo Candy Bar Discontinued, ,Sitemap,Sitemap